Dr. John O'Horo | sciencenewsnet.in

Breaking News

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

UW–Madison researchers find persistent problems with AI-assisted genomic studies

05 Nov, 2024

Mayo Clinic research shows bebtelovimab to be a reliable option for treating COVID-19 in era of BA.2, other subvariants

August 15, 2022 sarah JonasResearch Results

Mayo Clinic researchers say the monoclonal antibody bebtelovimab, already authorized by the Food and Drug Administration for emergency use on the omicron variant of COVID-19, is a reliable option to treat BA.2 and other COVID-19 subvariants. The findings of their multisite, retrospective study involving 3,607 high-risk patients appear in the Journal of Infectious Diseases.